Results 211 to 220 of about 4,942 (259)

Utility of the Consolidated Framework for Implementation Research for the patient perspective; comparison of the framework with a thematic analysis

Elvey R, Mathieson A, Wilson PM.
europepmc   +1 more source

Lipid-lowering agents in solid organ transplant recipients. [PDF]

Nephrol Dial Transplant
Mickiewicz A, Żegleń S, Kędzierska-Kapuza K, Heleniak Z, Frankiewicz A, Adamczyk E, Wełnicki M, Wawrzynowicz-Syczewska M, Raszeja-Wyszomirska J, Durlik M, Banach M, Dębska-Ślizień A, Gruchała M, Malyszko J.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Inclisiran in dyslipidemia

Drugs of Today, 2021
Cardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol
C E, Kosmas, A, Muñoz Estrella, A, Sourlas, D, Pantou   +3 more
openaire   +2 more sources

Inclisiran

Journal of Prescribing Practice
In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of posts on X. This month she is talking about #inclisiran
Julia Brandts, Kausik K. Ray
openaire   +2 more sources

▼Inclisiran: more hope less hype

Drug and Therapeutics Bulletin, 2022
Abstract
openaire   +2 more sources

Inclisiran: A Review in Hypercholesterolemia

American Journal of Cardiovascular Drugs, 2023
Inclisiran (Leqvio®) is a first-in-class, subcutaneously administered, small interfering RNA (siRNA) that prevents hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby decreasing circulating low-density lipoprotein cholesterol (LDL-C). In the EU, inclisiran is indicated in adults with primary hypercholesterolemia or mixed
openaire   +2 more sources

Inclisiran in primary prevention: reality or fiction?

European Heart Journal, 2022
This editorial refers to ‘Effect of inclisiran on lipids in primary prevention: the ORION-11 trial’, by K.K.
Gencer, Baris, Mach, François
openaire   +2 more sources

Inclisiran for the treatment of dyslipidemia

Expert Opinion on Investigational Drugs, 2018
Dyslipidemia is one of the most important risk factors for cardiovascular disease. Insufficient reduction in LDL-C from existing therapies in patients at high risk of atherogenic cardiovascular disease is an unmet clinical need. Circulating PCSK9 causes hypercholesterolemia by reducing LDL receptors in hepatocytes.
Toshiyuki Nishikido, Kausik K. Ray
openaire   +2 more sources